1
|
Socinski M, Wang X, Baggstrom M, Gu L, Stinchcombe T, Edelman M, Baker S, Mannuel H, Crawford J, Vokes E. Switch Maintenance With Sunitinib (S) in Advanced Non-Small Cell Lung Cancer (NSCLC): An Alliance (CALGB 30607), Randomized, Placebo-Controlled Phase 3 Trial. Int J Radiat Oncol Biol Phys 2014. [DOI: 10.1016/j.ijrobp.2014.08.022] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
2
|
Kwok Y, Wu Y, Mirmiran A, DiBiase S, Goloubeva O, Bridges B, Mannuel H, Dawson N, Amin P, Hussain A. Prospective Trial of Escalating Doses of Paclitaxel, Concurrent Radiation and Androgen Deprivation in High-risk Prostate Cancer with or without Prior Prostatectomy. Int J Radiat Oncol Biol Phys 2010. [DOI: 10.1016/j.ijrobp.2010.07.839] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
3
|
Wu Y, Kwok Y, Mirmiran A, Goloubeva O, Mannuel H, Dawson N, Amin P, Hussain A. Weekly paclitaxel (P) with concurrent external beam radiation (EBRT) and androgen deprivation therapy (ADT) in high-risk prostate cancer (PC) patients with or without prior prostatectomy (RP). J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.5122] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
5122 Background: EBRT with ADT (4 mos to 2–3 yrs) is standard treatment for high risk PC. In this trial, we evaluated weekly P given concurrently with EBRT and ADT in high risk PC. Methods: For pts undergoing RP, high risk was defined as: pT3 and/or pN+, M0, and/or rising PSA (> 0.5) post RP. For pts not undergoing RP (i.e. locally advanced PC [LAPC]) high risk included: cT2b-4N0, N+, M0; bGS 8–10; bGS ≥ 7 + PSA ≥ 10 but ≤ 150; and/or PSA ≥ 20 but ≤ 150. Treatment included ADT (4 or 24 mos, preplanned based on clinical presentation), P (40, 50, or 60 mg/m2/wk) x 7 with EBRT, and whole pelvis EBRT 45 Gy with 19.8 Gy boost (total 64.8 Gy) to prostate bed in RP pts and 25.2 Gy boost (total 70.2 Gy) to prostate in LAPC pts. Results: Between October 1999 and December 2006, 59 pts (29 W, 28 AA) were enrolled (n = 29 LAPC, n = 30 RP); median age 67 yrs, median PSA at trial entry 5.9 (27.5 LAPC, 1.6 RP), median GS 8. Pts were enrolled at different weekly doses of P: 40 mg/m2 n = 10 pts; 50 mg/m2 n = 31 pts; 60 mg/m2 n = 18 pts. ADT for 4 mos was given in 29 pts and for 24 mos in 30 pts. At 40 mg/m2 67/70 (96%), 50 mg/m2 202/217 (93%), and 60 mg/m2 98/126 (78%) planned doses of P were given. There were no acute grade 4 toxicities. Most common grade 3 toxicities were diarrhea 15%, urinary urgency or incontinence 10%, tenesmus 5%, and leukopenia 3%. Median duration of f/u was 75.3 mos, OS 78%, biochemical progression 24/59 (41%) pts, clinical progression 11/59 (19%) pts. Time to biochemical progression was similar between RP vs. LAPC (p = 0.17), between ADT 4 mos vs. 24 mos (p = 0.61), and between AA vs. W (p = 0.54). Conclusions: This trial establishes the feasibility of tri-modality therapy with ADT, EBRT and weekly paclitaxel in high risk PC, both in RP pts and in LAPC pts with intact prostate glands. The maximum tolerated dose of paclitaxel is 50 mg/m2 /wk when given weekly with concurrent radiation to the pelvis and hormone ablation. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- Y. Wu
- University of Maryland, Baltimore, MD; Georgetown University Medical Center, Washington, DC
| | - Y. Kwok
- University of Maryland, Baltimore, MD; Georgetown University Medical Center, Washington, DC
| | - A. Mirmiran
- University of Maryland, Baltimore, MD; Georgetown University Medical Center, Washington, DC
| | - O. Goloubeva
- University of Maryland, Baltimore, MD; Georgetown University Medical Center, Washington, DC
| | - H. Mannuel
- University of Maryland, Baltimore, MD; Georgetown University Medical Center, Washington, DC
| | - N. Dawson
- University of Maryland, Baltimore, MD; Georgetown University Medical Center, Washington, DC
| | - P. Amin
- University of Maryland, Baltimore, MD; Georgetown University Medical Center, Washington, DC
| | - A. Hussain
- University of Maryland, Baltimore, MD; Georgetown University Medical Center, Washington, DC
| |
Collapse
|
4
|
Koshy M, Battafarano R, Burrows W, Krasna M, Greenwald B, Mannuel H, Suntharalingam M. Predicting patterns of failure in esophageal cancer following tri-modality therapy: Why histology matters. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.4553] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
5
|
Rapoport AP, Guo C, Badros A, Hakimian R, Akpek G, Kiggundu E, Meisenberg B, Mannuel H, Takebe N, Fenton R, Bolaños-Meade J, Heyman M, Gojo I, Ruehle K, Natt S, Ratterree B, Withers T, Sarkodee-Adoo C, Phillips GL, Tricot G. Autologous stem cell transplantation followed by consolidation chemotherapy for relapsed or refractory Hodgkin's lymphoma. Bone Marrow Transplant 2004; 34:883-90. [PMID: 15517008 DOI: 10.1038/sj.bmt.1704661] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Relapse remains a major cause of treatment failure after autotransplantation (auto-PBSCT) for Hodgkin's disease (HD). The administration of non-crossresistant therapies during the post-transplant period may delay or prevent relapse. We prospectively studied the role of consolidation chemotherapy (CC) after auto-PBSCT in 37 patients with relapsed or refractory HD. Patients received high-dose gemcitabine-BCNU-melphalan and auto-PBSCT followed by involved-field radiation and up to four cycles of the DCEP-G regimen, which consisted of dexamethasone, cyclophosphamide, etoposide, cisplatin, gemcitabine given at 3 and 9 months post transplant alternating with a second regimen (DPP) of dexamethasone, cisplatin, paclitaxel at 6 and 12 months post transplant. The probabilities of event-free survival (EFS) and overall survival (OS) at 2.5 years were 59% (95% CI=42-76%) and 86% (95% CI=71-99%), respectively. In all, 17 patients received 54 courses of CC and 15 were surviving event free (2.5 years, EFS=87%). There were no treatment-related deaths during or after the CC phase. Post-transplant CC is feasible and well tolerated. The impact of this approach on EFS should be evaluated in a larger, randomized study.
Collapse
Affiliation(s)
- A P Rapoport
- University of Maryland Greenebaum Cancer Center, Baltimore, MD 21201, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Mannuel H, Dawson N, Guo C, Dorsey B, Besche M, Smoot J, Engstrom C, Hussain A. Phase I/II trial of weekly doxorubicin (Doxo)/docetaxel (Doce) followed by hormone ablation (HA) in recurrent prostate cancer (PC). J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.4765] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | - N. Dawson
- University of Maryland, Baltimore, MD
| | - C. Guo
- University of Maryland, Baltimore, MD
| | - B. Dorsey
- University of Maryland, Baltimore, MD
| | - M. Besche
- University of Maryland, Baltimore, MD
| | - J. Smoot
- University of Maryland, Baltimore, MD
| | | | | |
Collapse
|